206 related articles for article (PubMed ID: 34169794)
1. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
2. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Tan O; Bradshaw K; Carr BR
Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
[TBL] [Abstract][Full Text] [Related]
3. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
4. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study.
Mercier J; Morin M; Lemieux MC; Reichetzer B; Khalifé S; Dumoulin C
Menopause; 2016 Jul; 23(7):816-20. PubMed ID: 27219835
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
6. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
7. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women.
Nappi RE; Kotek M; Brešt'anský A; Giordan N; Tramentozzi E
Climacteric; 2020 Oct; 23(5):519-524. PubMed ID: 32396754
[No Abstract] [Full Text] [Related]
9. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
10. Vaginal Health in Menopausal Women.
Alvisi S; Gava G; Orsili I; Giacomelli G; Baldassarre M; Seracchioli R; Meriggiola MC
Medicina (Kaunas); 2019 Sep; 55(10):. PubMed ID: 31547180
[TBL] [Abstract][Full Text] [Related]
11. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.
Kingsberg SA; Larkin L; Krychman M; Parish SJ; Bernick B; Mirkin S
Menopause; 2019 Feb; 26(2):124-131. PubMed ID: 30130293
[TBL] [Abstract][Full Text] [Related]
12. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview.
Sinha A; Ewies AA
Climacteric; 2013 Jun; 16(3):305-12. PubMed ID: 23215675
[TBL] [Abstract][Full Text] [Related]
13. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
[TBL] [Abstract][Full Text] [Related]
14. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
15. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
[TBL] [Abstract][Full Text] [Related]
16. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Comini ACM; Carvalho BM; Moreira MJB; Reis PCA; Colapietro L; Northern J; Batalini F
Clin Breast Cancer; 2023 Dec; 23(8):835-846. PubMed ID: 37806915
[TBL] [Abstract][Full Text] [Related]
17. Ospemifene, vulvovaginal atrophy, and breast cancer.
Wurz GT; Soe LH; DeGregorio MW
Maturitas; 2013 Mar; 74(3):220-5. PubMed ID: 23332519
[TBL] [Abstract][Full Text] [Related]
18. Assessment of ospemifene or lubricants on clinical signs of VVA.
Constantine G; Graham S; Koltun WD; Kingsberg SA
J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
[TBL] [Abstract][Full Text] [Related]
19. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.
Potter N; Panay N
Climacteric; 2021 Feb; 24(1):19-24. PubMed ID: 32990054
[TBL] [Abstract][Full Text] [Related]
20. Treatment to External Labia and Vaginal Canal With CO2 Laser for Symptoms of Vulvovaginal Atrophy in Postmenopausal Women.
Samuels JB; Garcia MA
Aesthet Surg J; 2019 Jan; 39(1):83-93. PubMed ID: 29726916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
